James Anderson Provides Update on Holdings of MyndTec Inc.
Detroit, Michigan--(Newsfile Corp. - December 15, 2025) - James Anderson (the "Investor") announces update to his ownership of common shares in the capital of MyndTec Inc. (the "Issuer") (the "Common Shares") and common share purchase warrants of the Issuer (the "Warrants"). On December 12, 2025, the Issuer completed the ninth tranche (the "Ninth Tranche") of a private placement of units ("Units") announced on January 30, 2025. 553,926 Units we
Technology, Healthcare and Hospitals, Health
2025-12-15 5:25 PM EST | James Anderson
Adia Nutrition Inc. Announces IRB Approval from BeyondBound for Adia Med's Autism Clinical Study
Winter Park, Florida--(Newsfile Corp. - December 15, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine through its Adia Med subsidiary, today announced that the independent Institutional Review Board (IRB) BeyondBound has approved the company's patent-pending clinical study protocol focused on Autism Spectrum Disorder (ASD).
Healthcare and Hospitals, Health
2025-12-15 10:30 AM EST | Adia Nutrition Inc.
Apyron Pioneering Next Generation Pain Management Solutions
Atlanta, Georgia--(Newsfile Corp. - December 15, 2025) - Apyron, Inc. is a medical technology company with a product portfolio designed to address chronic pain and joint-related disorders, with a core value to restore mobility in patients and provide them agency over their therapy. Apyron's product portfolio is being developed to address two major contributors to disability — chronic lower back pain and joint disease. Chronic pain markets account for over $384 million of healthcare spe
Biotechnology, Healthcare and Hospitals, Health
2025-12-15 9:00 AM EST | Apyron, Inc.
CareRx Announces Q4 2025 Dividend
Toronto, Ontario--(Newsfile Corp. - December 15, 2025) - CareRx Corporation (TSX: CRRX) ("CareRx" or the "Company"), Canada's leading provider of pharmacy services to seniors living and other congregate care communities, today announced that the Company's Board of Directors has declared a dividend of CAD$0.02 per outstanding common share of the Company ("Common Shares"), payable on January 21, 2026, to holders of record of Common Shares as of the close of business on
2025-12-15 7:30 AM EST | CareRx Corporation
NervGen Pharma Announces Proposed Amendment to Warrants
Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other traumatic and neurologic disorders, today announced that the Company intends to amend 5,075,000 common share purchase warrants (the "2022 Warrants") that were issued pursuant to a private placement of units that c
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-12-12 7:51 PM EST | NervGen Pharma Corp.
MyndTec Inc. Completes Ninth Tranche of Non-Brokered Private Placement
Mississauga, Ontario--(Newsfile Corp. - December 12, 2025) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), a neurological treatment and rehabilitation medical technology company, is pleased to announce that it has closed the ninth tranche of its non-brokered private placement previously announced on January 30, 2025 (the "Offering"). The ninth tranche of the private placement consists of 553,926 Units of the Company (the "Units") at a price of $0.20 p
Technology, Healthcare and Hospitals, Health
2025-12-12 5:39 PM EST | MyndTec Inc.
Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing
Toronto, Ontario--(Newsfile Corp. - December 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, has commenced a non-brokered private placement of units of the Company ("Units") to raise up to $CAN 2,000,000 (&#
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2025-12-12 5:00 PM EST | Theralase Technologies Inc.
Healthcare Special Opportunities Fund Announces December 2025 Quarterly Distribution
Toronto, Ontario--(Newsfile Corp. - December 12, 2025) - LDIC Inc. (the "Manager"), the manager of Healthcare Special Opportunities Fund (TSX: MDS.UN) (the "Fund"), a closed-end investment fund, today announces the quarterly distribution of CDN$0.06136 per Class A unit and US$0.05468 per Class U unit. The distribution will be paid on or before December 30, 2025, to unitholders of record on December 15, 2025. For further information please co
Banking / Financial Services, Healthcare and Hospitals
2025-12-12 9:55 AM EST | Healthcare Special Opportunities Fund
Envoy Medical Completes First Set of Activations in Final Stage of Pivotal Clinical Study for its First-Of-Its-Kind Fully Implanted Acclaim(R) Cochlear Implant
White Bear Lake, Minnesota--(Newsfile Corp. - December 10, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the completion of the first set of activations in the final stage of the pivotal clinical study for the investigational fully implanted Acclaim® cochlear implant. These activations were performed at Shohet Ear Associates in Seal Beach, California and the C
Biotechnology, Healthcare and Hospitals
2025-12-10 8:00 AM EST | Envoy Medical, Inc.
Relief AI Inc. Announces Significant Milestones as Its Platform Adoption Accelerates
Toronto, Ontario--(Newsfile Corp. - December 10, 2025) - Relief AI Inc. (the "Company "or "Relief AI) is pleased to provide an update on the significant progress made over the past year as the company continues its mission to deliver the most advanced, holistic, and effective workplace wellness and well-being platform available today. Relief AI is a leading-edge workplace well-being platform designed specifically to identify and help employees address early signs of workplace bur
Technology, Healthcare and Hospitals, Health
2025-12-10 7:00 AM EST | Relief AI Inc.
HEALWELL AI Appoints Ian Kidson to Board of Directors
Toronto, Ontario--(Newsfile Corp. - December 10, 2025) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "
Technology, Healthcare and Hospitals
2025-12-10 3:15 AM EST | HEALWELL AI
Adia Nutrition Inc. Files SEC Form 10 as Strategic Step Toward Full Reporting Status
Winter Park, Florida--(Newsfile Corp. - December 8, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), announced today that, with the assistance of Adia's Chief Financial Officer, and following review by the Company's auditing accountant, its Form 10 registration statement was prepared and submitted by Adia's corporate accountant and legal counsel to the U.S. Securities and Exchange Commission (SEC).
Healthcare and Hospitals, Health
2025-12-08 9:00 AM EST | Adia Nutrition Inc.
Correction to MyndTec Inc. Press Release Issued December 3, 2025 Regarding Non-Brokered Private Placement
Mississauga, Ontario--(Newsfile Corp. - December 5, 2025) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), announced today a correction to its press release titled "MyndTec Inc. Completes Eighth Tranche of Non-Brokered Private Placement" issued on December 3, 2025 (the "Initial Press Release"). The Initial Press Release incorrectly stated the number of units issued under the eighth tranche of the private placement Offering as 351,475 Units, the aggregate
Technology, Healthcare and Hospitals, Health
2025-12-05 4:30 PM EST | MyndTec Inc.
Envoy Medical to Host Fireside Chat with CEO Brent Lucas and the First Acclaim(R) Cochlear Implant Patient
White Bear Lake, Minnesota--(Newsfile Corp. - December 4, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that it will host a fireside chat on Thursday, December 11, 2025, at 4:30 P.M. ET featuring a conversation between CEO Brent Lucas and Craig Eggert, the first patient to receive the Acclaim™ cochlear implant. Event: Envoy Medical Fireside Chat
Biotechnology, Healthcare and Hospitals
2025-12-04 8:00 AM EST | Envoy Medical, Inc.
MyndTec Inc. Completes Eighth Tranche of Non-Brokered Private Placement
Mississauga, Ontario--(Newsfile Corp. - December 3, 2025) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), a neurological treatment and rehabilitation medical technology company, is pleased to announce that it has closed the eighth tranche of its non-brokered private placement previously announced on January 30, 2025 (the "Offering"). The eighth tranche of the private placement consists of 351,475 Units of the Company (the "Units") at a price of $0.20
Technology, Healthcare and Hospitals, Health
2025-12-03 5:00 PM EST | MyndTec Inc.
Cosmo Announces Breakthrough Phase III Topline Results from Scalp 1 and Scalp 2 for Clascoterone 5% Solution in Male Hair Loss, Showing up to 539% Relative Improvement in Target-Area Hair Count vs Placebo; US and EU Submissions are Underway
Ad hoc announcement pursuant to Art. 53 LR 1,465 patients were randomized into the two identical-in-design clinical studies Scalp 1 (NCT05910450) and Scalp 2 (NCT05914805) Both studies reached statistically significant endpoints in TAHC (Target-Area Hair Count), with one reaching 539% relative improvement to placebo and the second study reaching 168% relative improvement to placebo Positive safety profile demonstrated
Healthcare and Hospitals, Health
2025-12-03 1:12 AM EST | Cosmo Pharmaceuticals N.V.
Envoy Medical Announces the Grant of Its 40th U.S. Patent
White Bear Lake, Minnesota--(Newsfile Corp. - December 2, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that it has received its 40th active U.S. Patent from the United States Patent and Trademark Office. The new patent further strengthens the Company's intellectual property portfolio, which includes an additional 45 issued foreign patents. U.S. Paten
Biotechnology, Healthcare and Hospitals
2025-12-02 8:00 AM EST | Envoy Medical, Inc.
FendX Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - December 1, 2025) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), an innovative surface protection company developing technology-based solutions to reduce the spread of harmful pathogens, announces the completion of its previously disclosed debt settlement from November 21, 2025. The Company issued 34,540 common shares (each, a "Share") at $0.74 per Share to settle $25,560 of debt
Technology, Healthcare and Hospitals, Health
2025-12-01 6:15 PM EST | FendX Technologies Inc.
Adia Med Partners with America's #1 Health Talk Show Host, Dr. Asa Andrew, to Bring Breakthrough Stem Cell Therapies to the Spotlight
Winter Park, Florida--(Newsfile Corp. - December 1, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), one of the nation's leaders in Stem Cell Technology is excited to announce a partnership with 3X Physician and Multi-Platform Media talk show personality Dr. Asa Andrew (known to his fans as Doctor Asa).
Healthcare and Hospitals, Health
2025-12-01 9:30 AM EST | Adia Nutrition Inc.
BioMark Diagnostics Collaborative Lung Cancer Screening Project Honored by ADRIQ during the 35th Innovation Awards Gala
Vancouver, British Columbia--(Newsfile Corp. - December 1, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technologies for early cancer detection, is honored to announce that the Company and its research partners from the Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval (IUCPQ-UL) were awarded the Innovation Award from Industrial Research Cluster during the 35th annual ADRIQ
Technology, Biotechnology, Healthcare and Hospitals
2025-12-01 8:30 AM EST | BioMark Diagnostics, Inc.